Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC-10004 in Subjects With Active Psoriatic Arthritis
Sponsor: Amgen
Listed as NCT00456092, this PHASE2 trial focuses on Psoriatic Arthritis and remains completed. Sponsored by Amgen, it has been updated 10 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jun 2020 — Jul 2020 [monthly]
Completed PHASE2
-
Nov 2019 — Jun 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Brückenau, Germany , Berlin, Germany , Brussels, Belgium , Burlington, Canada , Cologne, Germany , Diepenbeek, Belgium , Frankfurt, Germany , Hamburg, Germany , Hamilton, Canada , Heidelberg, Germany and 26 more locations